Product Center
Trivalent Influenza Virus Subunit Vaccine
Our investigational trivalent influenza virus subunit vaccine is designed to provide protection against two influenza A virus subtypes (H1N1 and H3N2) and one influenza B virus (Victoria lineage), which is consistent with the coverage recommended by the World Health Organization (WHO) for the 2024-2025 influenza season in the Northern Hemisphere. This investigational trivalent influenza virus vaccine leverages the mature formulation of our approved quadrivalent influenza virus subunit vaccine, using the same antigen stock solution, with the omission of one influenza B virus subtype (Yamagata) during formulation. Based on the preclinical and clinical results of our quadrivalent influenza virus subunit vaccine, the investigational trivalent influenza virus subunit vaccines (intended for populations aged 3 years and above, and those aged 6-35 months respectively) are expected to obtain marketing approval in Q4 2025.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
- Rrecommend Products
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
